

Role of vascular endothelial growth factor in physiologi Therapeutic implications

Seminars in Oncology

29, 10-14

DOI: [10.1053/sonc.2002.37264](https://doi.org/10.1053/sonc.2002.37264)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. <i>Blood</i> , 2002, 100, 1795-1801.	0.6	206
4	HÄmatopoetische und lymphatische Systemerkrankungen sowie solide Tumoren in der Schwangerschaft. <i>Onkologe</i> , 2002, 8, 1333-1340.	0.7	4
5	Therapeutic Angiogenesis: A Complex Problem Requiring a Sophisticated Approach. <i>Cardiovascular Toxicology</i> , 2003, 3, 283-298.	1.1	20
6	Combination of Vascular Endothelial Growth Factor (VEGF) and Thymidine Phosphorylase (TP) to Improve Angiogenic Gene Therapy. <i>Angiogenesis</i> , 2003, 6, 185-192.	3.7	5
7	Norepinephrine Upregulates Vascular Endothelial Growth Factor in Rat Cardiac Myocytes by a Paracrine Mechanism. <i>Angiogenesis</i> , 2003, 6, 303-309.	3.7	30
8	Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. <i>Diabetologia</i> , 2003, 46, 1483-1488.	2.9	222
9	Expression of the VEGF receptor-3 in osteoarthritic chondrocytes: stimulation by interleukin-1 β and association with β 1-integrins. <i>Histochemistry and Cell Biology</i> , 2003, 120, 235-241.	0.8	19
10	VEGF-receptor signal transduction. <i>Trends in Biochemical Sciences</i> , 2003, 28, 488-494.	3.7	563
11	Therapeutic approaches to bladder cancer: identifying targets and mechanisms. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 67-83.	2.0	44
12	Targeted therapy for epithelial ovarian cancer: Current status and future prospects. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 701-734.	1.2	43
14	Out of air is not out of action. <i>Nature</i> , 2003, 423, 593-595.	13.7	158
15	Blood vessels and nerves: common signals, pathways and diseases. <i>Nature Reviews Genetics</i> , 2003, 4, 710-720.	7.7	456
16	Vascular endothelial growth factor and the pathogenesis of emphysema. <i>American Journal of Medicine</i> , 2003, 114, 413-414.	0.6	16
17	Cortical and retinal defects caused by dosage-dependent reductions in VEGF-A paracrine signaling. <i>Developmental Biology</i> , 2003, 262, 225-241.	0.9	243
18	An overview of targeted treatments in cancer. <i>Clinical Therapeutics</i> , 2003, 25, 2121-2137.	1.1	85
19	The Role of Vascular Endothelial Growth Factor in Wound Healing. <i>International Journal of Lower Extremity Wounds</i> , 2003, 2, 107-120.	0.6	101
20	Microenvironmental and cellular consequences of altered blood flow in tumours. <i>British Journal of Radiology</i> , 2003, 76, S11-S22.	1.0	204
21	Colorectal Cancer in the Elderly. <i>Drugs and Aging</i> , 2003, 20, 1-11.	1.3	21

#	ARTICLE	IF	CITATIONS
22	Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12718-12723.	3.3	321
23	Snake Venom Vascular Endothelial Growth Factors (VEGFs) Exhibit Potent Activity through Their Specific Recognition of KDR (VEGF Receptor 2). Journal of Biological Chemistry, 2003, 278, 51985-51988.	1.6	113
24	Tumor Microenvironment and Hemorheological Abnormalities. Seminars in Thrombosis and Hemostasis, 2003, 29, 489-498.	1.5	31
25	Serum and Drainage Fluid Vascular Endothelial Growth Factor Levels in Early Surgical Wounds. European Surgical Research, 2003, 35, 492-496.	0.6	52
26	The Transjugular Intrahepatic Portosystemic Stent-Shunt (TIPS) as Rescue Therapy for Complete Budd-Chiari Syndrome and Portal Vein Thrombosis. Zeitschrift Fur Gastroenterologie, 2003, 41, 413-418.	0.2	24
27	Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell non-Hodgkin's lymphoma: a phase II study. Anti-Cancer Drugs, 2003, 14, 809-815.	0.7	9
28	Gene Expression Profiling of Renal Cell Carcinoma and Its Implications in Diagnosis, Prognosis, and Therapeutics. Advances in Cancer Research, 2003, 89, 157-181.	1.9	31
29	Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood, 2003, 101, 2328-2334.	0.6	101
30	Angiogenesis Inhibitors: Current & Future Directions. Current Pharmaceutical Design, 2004, 10, 1-9.	0.9	26
31	Angiogenesis: a potential target for therapy of soft tissue sarcomas. , 2004, 120, 169-180.		3
32	Angiogenesis in Multiple Myeloma: Implications in Myeloma Therapy. Cancer Reviews: Asia-Pacific, 2004, 02, 119-129.	0.1	2
33	Identification and Biological Characterization of Angiogenic and Tumor Growth Inhibitors derived from Sinica cetorhinus maximum Cartilage. Marine Drugs, 2004, 2, 30-38.	2.2	5
34	Radioimmunotherapy with engineered antibodies. Expert Opinion on Biological Therapy, 2004, 4, 217-231.	1.4	20
35	Antiangiogenesis Therapy for Endometriosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1089-1095.	1.8	215
36	Oncogenes as Regulators of Tissue Factor Expression in Cancer: Implications for Tumor Angiogenesis and Anti-Cancer Therapy. Seminars in Thrombosis and Hemostasis, 2004, 30, 21-30.	1.5	51
37	Complex Role of Heme Oxygenase-1 in Angiogenesis. Antioxidants and Redox Signaling, 2004, 6, 858-866.	2.5	80
38	Abnormal vascular, platelet and coagulation markers in primary thrombocythaemia are not reversed by treatments that reduce the platelet count. Platelets, 2004, 15, 447-449.	1.1	12
39	Novel Mechanism of Action for Hydralazine. Circulation Research, 2004, 95, 162-169.	2.0	125

#	ARTICLE	IF	CITATIONS
40	Interleukin-1 β Regulates Angiopoietin-1 Expression in Human Endothelial Cells. <i>Cancer Research</i> , 2004, 64, 3186-3190.	0.4	59
41	Progesterin-Dependent Induction of Vascular Endothelial Growth Factor in Human Breast Cancer Cells. <i>Cancer Research</i> , 2004, 64, 2238-2244.	0.4	53
43	VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant. <i>Cancer Research</i> , 2004, 64, 7822-7835.	0.4	416
44	Tumor-specific Ab-mediated targeting of MHC-peptide complexes induces regression of human tumor xenografts in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9051-9056.	3.3	34
45	Control of the Vascular Endothelial Growth Factor Internal Ribosome Entry Site (IRES) Activity and Translation Initiation by Alternatively Spliced Coding Sequences. <i>Journal of Biological Chemistry</i> , 2004, 279, 18717-18726.	1.6	54
46	Sp1 Is Involved in Akt-mediated Induction of VEGF Expression through an HIF-1-independent Mechanism. <i>Molecular Biology of the Cell</i> , 2004, 15, 4841-4853.	0.9	206
47	Identification and validation of cell surface antigens for antibody targeting in oncology. <i>Endocrine-Related Cancer</i> , 2004, 11, 659-687.	1.6	109
48	Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15949-15954.	3.3	552
49	Vascular Endothelial Growth Factor and Matrix Metalloproteinase 9 Expression in Human Carotid Atherosclerotic Plaques: Relationship with Plaque Destabilization via Neovascularization. <i>Cerebrovascular Diseases</i> , 2004, 18, 160-165.	0.8	34
50	Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone. <i>International Journal of Molecular Medicine</i> , 2004, 14, 707.	1.8	8
51	Raising the Bar: How HIF-1 Helps Determine Tumor Radiosensitivity. <i>Cell Cycle</i> , 2004, 3, 1105-1108.	1.3	44
52	Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 893-901.	1.3	317
53	A Novel Orally Bioavailable Inhibitor of Kinase Insert Domain-Containing Receptor Induces Antiangiogenic Effects and Prevents Tumor Growth in Vivo. <i>Cancer Research</i> , 2004, 64, 751-756.	0.4	25
54	The Homeobox Transcription Factor Hox D3 Promotes Integrin $\alpha 5 \beta 1$ Expression and Function during Angiogenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 4862-4868.	1.6	114
55	Fludarabine-Induced Apoptosis in CD19+ α /CD5+ B-CLL Cells is a Direct and Nurse-Like-Cell Independent Effect. <i>Leukemia and Lymphoma</i> , 2004, 45, 2307-2314.	0.6	1
56	Novel Agents in Epithelial Ovarian Cancer. <i>Cancer Investigation</i> , 2004, 22, 29-44.	0.6	16
57	Phase I Study of the Humanized Antiepidermal Growth Factor Receptor Monoclonal Antibody EMD72000 in Patients With Advanced Solid Tumors That Express the Epidermal Growth Factor Receptor. <i>Journal of Clinical Oncology</i> , 2004, 22, 175-184.	0.8	257
58	Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer. <i>Cancer Research</i> , 2004, 64, 1765-1772.	0.4	148

#	ARTICLE	IF	CITATIONS
59	Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 286, F767-F773.	1.3	85
60	The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. <i>Kidney International</i> , 2004, 65, 2003-2017.	2.6	411
61	Angiogenesis: now and then. <i>Apmis</i> , 2004, 112, 402-412.	0.9	56
62	Nucleoside transporters in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2004, 18, 385-393.	3.3	97
63	Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. <i>Oncogene</i> , 2004, 23, 4624-4635.	2.6	70
64	Metastatic squamous cell carcinoma cells that overexpress c-Met exhibit enhanced angiogenesis factor expression, scattering and metastasis in response to hepatocyte growth factor. <i>Oncogene</i> , 2004, 23, 6199-6208.	2.6	57
65	HIF1 and oxygen sensing in the brain. <i>Nature Reviews Neuroscience</i> , 2004, 5, 437-448.	4.9	506
66	Gefitinib (Iressa™, ZD1839) and new epidermal growth factor receptor inhibitors. <i>British Journal of Cancer</i> , 2004, 90, 566-572.	2.9	75
67	Neuroprotection of Ischemic Brain by Vascular Endothelial Growth Factor is Critically Dependent on Proper Dosage and May Be Compromised by Angiogenesis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 693-702.	2.4	120
68	Are Natural Products Still of Interest Compared with Molecular-Targeted Therapy for the Treatment of Cancer?. <i>Clinical Lung Cancer</i> , 2004, 5, 313.	1.1	1
69	Angiogenesis inhibitors in the treatment of colorectal cancer. <i>Seminars in Oncology</i> , 2004, 31, 10-16.	0.8	52
70	Molecular targeting of angiogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2004, 1654, 39-49.	3.3	40
71	Loss of HIF-1 α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. <i>Cancer Cell</i> , 2004, 6, 485-495.	7.7	494
72	Microvessels Promote Motor Nerve Survival and Regeneration Through Local VEGF Release Following Ectopic Reattachment. <i>Microcirculation</i> , 2004, 11, 633-644.	1.0	27
73	Involvement of ERK1/2 pathway in TGF- β 1-induced VEGF secretion in normal human cytotrophoblast cells. <i>Molecular Reproduction and Development</i> , 2004, 68, 198-204.	1.0	40
74	Vascular Endothelial Growth Factor and Other Signaling Pathways in Developmental and Pathologic Angiogenesis. <i>International Journal of Hematology</i> , 2004, 80, 7-20.	0.7	29
75	Gene transfer of CuZn superoxide dismutase enhances the synthesis of vascular endothelial growth factor. <i>Molecular and Cellular Biochemistry</i> , 2004, 264, 169-181.	1.4	35
76	Effect of reduced oxygen tension on reactive oxygen species production and activity of antioxidant enzymes in swine granulosa cells. <i>BioFactors</i> , 2004, 20, 61-69.	2.6	35

#	ARTICLE	IF	CITATIONS
77	Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. <i>Angiogenesis</i> , 2004, 7, 335-345.	3.7	375
78	In situ-formed, tissue-adhesive co-gel composed of styrenated gelatin and styrenated antibody: potential use for local anti-cytokine antibody therapy on surgically resected tissues. <i>Biomaterials</i> , 2004, 25, 5867-5873.	5.7	15
79	Integration of novel agents in the treatment of colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54 Suppl 1, S32-9.	1.1	29
80	Thalidomide in POEMS syndrome: Case report. <i>American Journal of Hematology</i> , 2004, 76, 66-68.	2.0	73
81	VEGF-R2 and neuropilin-1 are involved in VEGF-A-induced differentiation of human bone marrow progenitor cells. <i>Journal of Cellular Physiology</i> , 2004, 200, 351-359.	2.0	30
82	Targeting the EGFR in neoplasia—more questions than answers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 899-902.	0.4	2
83	Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. <i>Biomaterials</i> , 2004, 25, 2789-2798.	5.7	152
84	The Genetics of Sporadic Colon Cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2004, 15, 128-135.	0.2	3
85	Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2004, 43, 215-222.	0.9	87
86	The Baboon as a Nonhuman Primate Model for the Study of Human Reproduction. <i>Gynecologic and Obstetric Investigation</i> , 2004, 57, 1-60.	0.7	19
87	Biologic therapy of liver tumors. <i>Surgical Clinics of North America</i> , 2004, 84, 673-696.	0.5	7
88	Inhibition of Tumor Growth and Angiogenesis by Soluble EphB4. <i>Neoplasia</i> , 2004, 6, 248-257.	2.3	104
89	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. <i>Drug Resistance Updates</i> , 2004, 7, 125-138.	6.5	73
90	The effects of reduced oxygen tension on swine granulosa cell. <i>Regulatory Peptides</i> , 2004, 120, 69-75.	1.9	68
91	Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts. <i>American Journal of Pathology</i> , 2004, 165, 35-52.	1.9	702
92	N-Acetyl-Cysteine Promotes Angiostatin Production and Vascular Collapse in an Orthotopic Model of Breast Cancer. <i>American Journal of Pathology</i> , 2004, 164, 1683-1696.	1.9	62
93	Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. <i>Oncogene</i> , 2004, 23, 1618-1626.	2.6	50
94	Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor. <i>Cancer Research</i> , 2004, 64, 3586-3592.	0.4	65

#	ARTICLE	IF	CITATIONS
95	Heritability of circulating growth factors involved in the angiogenesis in healthy human population. <i>Cytokine</i> , 2004, 27, 152-158.	1.4	31
96	Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. <i>Seminars in Hematology</i> , 2004, 41, 10-14.	1.8	41
97	Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. <i>Clinical Neurology and Neurosurgery</i> , 2004, 106, 289-293.	0.6	45
98	Modulation of angiogenesis in patients with myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 623-639.	0.7	11
99	VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2004, 104, 788-794.	0.6	195
100	Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia. <i>Blood</i> , 2004, 104, 495-501.	0.6	82
101	Fenretinide enhances rituximab-induced cytotoxicity against B-cell lymphoma xenografts through a caspase-dependent mechanism. <i>Blood</i> , 2004, 103, 3516-3520.	0.6	33
102	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004, 104, 3064-3071.	0.6	558
103	Adeno-associated virus mediated gene therapy for vascular retinopathies. <i>Laboratory Techniques in Biochemistry and Molecular Biology / Edited By T S Work [and] E Work</i> , 2005, , 103-123.	0.2	1
104	Role of monocytes and macrophages in angiogenesis. , 2005, , 127-146.		27
105	Contrast Agents for Magnetic Resonance Imaging. , 2005, , 23-37.		3
106	The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan. <i>Anti-Cancer Drugs</i> , 2005, 16, 1099-1108.	0.7	25
107	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , 2005, 105, 2099-2106.	0.6	40
108	A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. <i>Blood</i> , 2005, 105, 2504-2509.	0.6	67
109	Genetic Variations in Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase and Their Contributions to Human Disease. <i>Microcirculation</i> , 2005, 12, 129-140.	1.0	14
110	VEGF as a Therapeutic Target in Cancer. <i>Oncology</i> , 2005, 69, 11-16.	0.9	513
111	EGCG, a major component of green tea, inhibits VEGF production by swine granulosa cells. <i>BioFactors</i> , 2005, 23, 25-33.	2.6	20
112	Angiogenesis: update 2005. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1835-1842.	1.9	272

#	ARTICLE	IF	CITATIONS
113	Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2. <i>British Journal of Haematology</i> , 2005, 129, 138-150.	1.2	101
114	Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. <i>British Journal of Cancer</i> , 2005, 93, 107-115.	2.9	133
115	VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. <i>EMBO Journal</i> , 2005, 24, 2342-2353.	3.5	243
116	Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. <i>Leukemia</i> , 2005, 19, 64-68.	3.3	58
117	Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. <i>Oncogene</i> , 2005, 24, 4701-4709.	2.6	99
118	First-Line Treatment with Bevacizumab and Paclitaxel Prolongs Progression-Free Survival in Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2005, 6, 105-107.	1.1	6
119	The epidermal growth factor receptor as a target for colorectal cancer therapy. <i>Seminars in Oncology</i> , 2005, 32, 52-60.	0.8	84
120	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2005, 205, 246-252.	2.0	26
121	Protein expression and gene amplification of epidermal growth factor receptor in thymomas. <i>Cancer</i> , 2005, 103, 630-636.	2.0	78
122	Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. <i>Journal of Surgical Oncology</i> , 2005, 91, 173-180.	0.8	471
123	Nitric oxide modulation of low-density mononuclear cell transendothelial migration. <i>Microsurgery</i> , 2005, 25, 452-456.	0.6	6
124	Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. <i>Rheumatology International</i> , 2005, 26, 162-167.	1.5	24
125	Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 55, 67-81.	2.0	24
126	Effect of VEGF on Mouse Thymocyte Proliferation and Apoptosis In Vitro. <i>Bulletin of Experimental Biology and Medicine</i> , 2005, 139, 576-579.	0.3	3
127	Anti-angiogenic strategies in gastrointestinal malignancies. <i>Current Treatment Options in Oncology</i> , 2005, 6, 411-421.	1.3	14
128	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 413-425.	1.9	24
129	Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications. <i>Oncology Reports</i> , 2005, 14, 1565.	1.2	1
130	A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model. <i>Clinical Cancer Research</i> , 2005, 11, 2662-2669.	3.2	111

#	ARTICLE	IF	CITATIONS
131	Antivascular Endothelial Growth Factor Monoclonal Antibody Therapy: A Promising Paradigm in Colorectal Cancer. <i>Clinical Journal of Oncology Nursing</i> , 2005, 9, 55-60.	0.3	12
132	Growth factor signal transduction defects in the cardiovascular system. <i>Cardiovascular Research</i> , 2005, 65, 574-580.	1.8	14
133	Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. <i>Journal of Carcinogenesis</i> , 2005, 4, 16.	2.5	18
134	Antibody phage display technologies with special reference to angiogenesis. <i>FASEB Journal</i> , 2005, 19, 331-341.	0.2	30
135	RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer. <i>Cancer Research</i> , 2005, 65, 6882-6890.	0.4	58
136	Concomitant Administration of Bevacizumab, Irinotecan, 5-Fluorouracil, and Leucovorin: Nonclinical Safety and Pharmacokinetics. <i>International Journal of Toxicology</i> , 2005, 24, 357-363.	0.6	13
137	Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti- $\alpha_v\beta_3$ Integrin Monoclonal Antibody, Despite Widespread Tissue Binding. <i>Clinical Cancer Research</i> , 2005, 11, 6959-6965.	3.2	42
138	Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia. <i>Vascular Medicine</i> , 2005, 10, 15-22.	0.8	23
139	A Hypoxia-Driven Vascular Endothelial Growth Factor/Flt1 Autocrine Loop Interacts with Hypoxia-Inducible Factor-1 α through Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase 1/2 Pathway in Neuroblastoma. <i>Cancer Research</i> , 2005, 65, 7267-7275.	0.4	119
141	Therapeutic potential of inhibitory VEGF splice variants. <i>Future Oncology</i> , 2005, 1, 467-473.	1.1	21
142	Ligand- and Cell-Specific Effects of Signal Transduction Pathway Inhibitors on Progesterin-Induced Vascular Endothelial Growth Factor Levels in Human Breast Cancer Cells. <i>Molecular Endocrinology</i> , 2005, 19, 312-326.	3.7	28
143	Proliferation of Endothelial and Tumor Epithelial Cells by Progesterin-Induced Vascular Endothelial Growth Factor from Human Breast Cancer Cells: Paracrine and Autocrine Effects. <i>Endocrinology</i> , 2005, 146, 3632-3641.	1.4	65
144	The biology of vascular endothelial growth factors. <i>Cardiovascular Research</i> , 2005, 65, 550-563.	1.8	680
145	Careful Decoy Receptor Titering is Required to Inhibit Tumor Angiogenesis While Avoiding Adversely Altering VEGF Bioavailability. <i>Molecular Therapy</i> , 2005, 11, 300-310.	3.7	20
146	Delivery of Antiangiogenic Agents for Cancer Gene Therapy. <i>Technology in Cancer Research and Treatment</i> , 2005, 4, 331-341.	0.8	5
147	The Clinical Use of Tumor Markers in Select Cancers: Are You Confident Enough to Discuss Them With Your Patients?. <i>Oncology Nursing Forum</i> , 2005, 32, 1013-1025.	0.5	4
148	Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions. <i>Journal of Clinical Oncology</i> , 2005, 23, 1295-1311.	0.8	196
149	Inhibition of Tumor Growth, Angiogenesis, and Tumor Cell Proliferation by a Small Molecule Inhibitor of c-Jun N-terminal Kinase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 325-332.	1.3	61

#	ARTICLE	IF	CITATIONS
150	Use of Reverse Phase Protein Microarrays and Reference Standard Development for Molecular Network Analysis of Metastatic Ovarian Carcinoma. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 346-355.	2.5	278
151	Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis. <i>Cancer Research</i> , 2005, 65, 5848-5856.	0.4	44
152	Managing Patients Treated with Bevacizumab Combination Therapy. <i>Oncology</i> , 2005, 69, 25-33.	0.9	265
153	Effect of 17 β -estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. <i>Fertility and Sterility</i> , 2005, 84, 485-491.	0.5	25
154	Microvascular density, vascular endothelial growth factor A, and its receptors in endometrial blood vessels in patients with menorrhagia. <i>Fertility and Sterility</i> , 2005, 84, 692-700.	0.5	19
155	Inhibition of Src Kinase Activity by Ad-mda7 Suppresses Vascular Endothelial Growth Factor Expression in Prostate Carcinoma Cells. <i>Molecular Therapy</i> , 2005, 12, 707-715.	3.7	47
157	Angiogenesis. <i>Circulation</i> , 2005, 111, 1556-1566.	1.6	400
158	Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 3697-3705.	0.8	876
159	Inhibition of Cell Proliferation and in Vitro Markers of Angiogenesis by Indole-3-carbinol, a Major Indole Metabolite Present in Cruciferous Vegetables. <i>Journal of Agricultural and Food Chemistry</i> , 2005, 53, 5164-5169.	2.4	37
161	p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005, 93, 173-182.	1.2	30
162	Epigallocatechin-3-gallate from green tea negatively affects swine granulosa cell function. <i>Domestic Animal Endocrinology</i> , 2005, 28, 243-256.	0.8	33
163	Growth factors and their relationship to neoplastic and paraneoplastic disease. <i>European Journal of Internal Medicine</i> , 2005, 16, 83-94.	1.0	3
164	Gastrointestinal cancer: recent developments in medical oncology. <i>European Journal of Surgical Oncology</i> , 2005, 31, 453-460.	0.5	25
165	Human peripheral blood eosinophils induce angiogenesis. <i>International Journal of Biochemistry and Cell Biology</i> , 2005, 37, 628-636.	1.2	111
166	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. <i>American Journal of Pathology</i> , 2005, 167, 1599-1607.	1.9	43
167	Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. <i>American Journal of Cancer</i> , 2005, 4, 15-34.	0.4	4
168	Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. <i>Gene Therapy</i> , 2005, 12, 762-771.	2.3	62
169	Cancer Drug Resistance. , 2006, , .		21

#	ARTICLE	IF	CITATIONS
170	A review on pro- and anti-angiogenic factors as targets of clinical intervention. <i>Pharmacological Research</i> , 2006, 53, 89-103.	3.1	138
171	JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility. <i>Journal of Molecular Diagnostics</i> , 2006, 8, 397-411.	1.2	70
172	Malignant mesothelioma. <i>Community Oncology</i> , 2006, 3, 215-224.	0.2	1
173	Antivascular Endothelial Growth Factor Agents and Their Development: Therapeutic Implications in Ocular Diseases. <i>American Journal of Ophthalmology</i> , 2006, 142, 660-668.e1.	1.7	132
174	Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 31-38.	1.0	45
175	Significance of vascular stabilization for tumor growth and metastasis. <i>Cancer Letters</i> , 2006, 238, 180-187.	3.2	20
176	Interaction Between Stromal Fibroblasts and Colorectal Cancer Cells in the Expression of Vascular Endothelial Growth Factor. <i>Journal of Surgical Research</i> , 2006, 134, 270-277.	0.8	22
177	Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. <i>Developmental Biology</i> , 2006, 296, 177-189.	0.9	273
178	Superior Cervical Ganglionectomy Induces Changes in Growth Factor Expression in the Rat Retina. , 2006, 47, 439.		22
179	Clinical Laboratory Tools to Diagnose Inflammation. <i>Advances in Clinical Chemistry</i> , 2006, 41, 189-229.	1.8	37
180	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006, 107, 4122-4129.	0.6	156
181	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 1002-1009.	0.5	86
182	Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies. <i>Current Pharmaceutical Design</i> , 2006, 12, 111-128.	0.9	19
183	Effects of 17 β -estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 560-563.	1.2	15
184	A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography. <i>Cancer Science</i> , 2006, 97, 1274-1278.	1.7	11
185	Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun. <i>Nature Biotechnology</i> , 2006, 24, 856-863.	9.4	104
186	HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. <i>Oncogene</i> , 2006, 25, 6986-6996.	2.6	154
187	Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression. <i>Oncogene</i> , 2006, 25, 7260-7266.	2.6	55

#	ARTICLE	IF	CITATIONS
188	Role of angiogenesis in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 515-523.	0.9	95
189	Hit-to-lead optimization of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of KDR kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4371-4375.	1.0	27
190	Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. <i>Biomaterials</i> , 2006, 27, 1868-1875.	5.7	144
191	Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. <i>Biomaterials</i> , 2006, 27, 5935-5943.	5.7	111
192	VEGF Trap Abolishes Shear Stress- and Overload-Dependent Angiogenesis in Skeletal Muscle. <i>Microcirculation</i> , 2006, 13, 499-509.	1.0	58
193	Modulation of VEGF/Flk-1 receptor expression in the rat pituitary GH3 cell line by growth factors. <i>Pituitary</i> , 2006, 9, 137-143.	1.6	4
194	A phase I Study with oral SU5416 in patients with advanced solid tumors: A drug inducing its clearance. <i>Investigational New Drugs</i> , 2006, 24, 299-304.	1.2	10
195	Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. <i>Biomaterials</i> , 2006, 27, 5242-5251.	5.7	304
196	Contraindications of VEGF-based therapeutic angiogenesis: Effects on macrophage density and histology of normal and ischemic brains. <i>Vascular Pharmacology</i> , 2006, 44, 316-325.	1.0	41
197	Bowel Perforation from Bevacizumab for the Treatment of Metastatic Colon Cancer: Incidence, Etiology, and Management. <i>Journal of Surgical Education</i> , 2006, 63, 334-337.	0.7	92
198	Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway. <i>Seminars in Oncology</i> , 2006, 33, 392-406.	0.8	319
199	Isolation and characterization of lymphatic microvascular endothelial cells from human tonsils. <i>Journal of Cellular Physiology</i> , 2006, 207, 107-113.	2.0	34
200	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. <i>Journal of Cellular Physiology</i> , 2006, 207, 158-164.	2.0	33
201	COX-2 upregulation in thymomas and thymic carcinomas. <i>International Journal of Cancer</i> , 2006, 119, 2063-2070.	2.3	16
202	Antagonistic Functions of Tetradecanoyl Phorbol Acetate-Inducible-Sequence 11b and HuR in the Hormonal Regulation of Vascular Endothelial Growth Factor Messenger Ribonucleic Acid Stability by Adrenocorticotropin. <i>Molecular Endocrinology</i> , 2006, 20, 916-930.	3.7	35
203	Effects of Anagrelide on Megakaryopoiesis and Platelet Production. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 352-361.	1.5	21
205	Cross Talk between the Cardiovascular and Nervous Systems: Neurotrophic Effects of Vascular Endothelial Growth Factor (VEGF) and Angiogenic Effects of Nerve Growth Factor (NGF)-Implications in Drug Development. <i>Current Pharmaceutical Design</i> , 2006, 12, 2609-2622.	0.9	147
206	Metabolism-Directed Optimisation of Antithrombotics: The Prodrug Principle. <i>Current Pharmaceutical Design</i> , 2006, 12, 73-91.	0.9	24

#	ARTICLE	IF	CITATIONS
207	VEGF Inhibitors in Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2006, 12, 387-394.	0.9	102
208	Vascular endothelial growth factor biology: clinical implications for ocular treatments. <i>British Journal of Ophthalmology</i> , 2006, 90, 1542-1547.	2.1	149
209	Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 2628-2633.	3.2	41
210	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. <i>Endocrine-Related Cancer</i> , 2006, 13, 905-919.	1.6	125
211	Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 104-113.	1.9	58
212	Effect of Connective Tissue Growth Factor on Hypoxia-Inducible Factor 1 α Degradation and Tumor Angiogenesis. <i>Journal of the National Cancer Institute</i> , 2006, 98, 984-995.	3.0	74
213	Ocular Angiogenesis. , 2006, , .		5
214	Does the EGFR and VEGF Expression Predict the Prognosis in Colon Cancer?. <i>European Surgical Research</i> , 2006, 38, 540-544.	0.6	27
215	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. <i>Human Reproduction</i> , 2006, 21, 2408-2416.	0.4	83
216	Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. <i>FASEB Journal</i> , 2006, 20, 1924-1926.	0.2	122
217	Hypoxic Regulation of Vascular Endothelial Growth Factor through the Induction of Phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc*. <i>Journal of Biological Chemistry</i> , 2006, 281, 13957-13963.	1.6	85
218	The Microtubule Binding Drug Lauimalide Inhibits Vascular Endothelial Growth Factor-Induced Human Endothelial Cell Migration and Is Synergistic when Combined with Docetaxel (Taxotere). <i>Molecular Pharmacology</i> , 2006, 69, 1207-1215.	1.0	57
219	Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin α , β Fab. <i>Journal of Biological Chemistry</i> , 2006, 281, 6625-6631.	1.6	162
220	Putting the brakes on angiogenesis through a novel VEGF α -KLH (kinoid) vaccine. <i>Expert Review of Vaccines</i> , 2007, 6, 491-496.	2.0	2
221	Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 771-782.	1.5	5
222	mda-7 in Combination with Bevacizumab Treatment Produces a Synergistic and Complete Inhibitory Effect on Lung Tumor Xenograft. <i>Molecular Therapy</i> , 2007, 15, 287-294.	3.7	41
223	Activation of Growth Factor Receptors in Esophageal Cancer α Implications for Therapy. <i>Oncologist</i> , 2007, 12, 1165-1177.	1.9	31
224	Tristetraprolin Inhibits Ras-dependent Tumor Vascularization by Inducing Vascular Endothelial Growth Factor mRNA Degradation. <i>Molecular Biology of the Cell</i> , 2007, 18, 4648-4658.	0.9	100

#	ARTICLE	IF	CITATIONS
225	Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2198-2208.	1.9	54
226	Chemoprevention of Colorectal Cancer. <i>Digestion</i> , 2007, 76, 51-67.	1.2	72
227	Des- β -carboxyl Prothrombin-promoted Vascular Endothelial Cell Proliferation and Migration. <i>Journal of Biological Chemistry</i> , 2007, 282, 8741-8748.	1.6	58
228	Targeted agents in the treatment of pancreatic cancer: history and lessons learned. <i>Current Opinion in Oncology</i> , 2007, 19, 390-395.	1.1	9
229	Vascular endothelial growth factor family of ligands and receptors: Review. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 38, 258-268.	0.6	304
230	The structure of the vascular network of tumors. <i>Cancer Letters</i> , 2007, 248, 18-23.	3.2	97
231	The developing trend of monoclonal antibodies in the treatment of colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 871-883.	1.4	6
232	The Role of VEGF and EGFR Inhibition: Implications for Combining Anti-VEGF and Anti-EGFR Agents. <i>Molecular Cancer Research</i> , 2007, 5, 203-220.	1.5	378
233	Mathematical models of the VEGF receptor and its role in cancer therapy. <i>Journal of the Royal Society Interface</i> , 2007, 4, 283-304.	1.5	24
234	Design, Synthesis, and Evaluation of Orally Active Benzimidazoles and Benzoxazoles as Vascular Endothelial Growth Factor-2 Receptor Tyrosine Kinase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 4351-4373.	2.9	143
235	Neuropilin-1 Modulates p53/Caspases Axis to Promote Endothelial Cell Survival. <i>PLoS ONE</i> , 2007, 2, e1161.	1.1	60
236	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. <i>Journal of Cellular Physiology</i> , 2007, 213, 229-236.	2.0	11
237	Identification of novel genes expressed in hypoxic brain condition by fluorescence differential display. <i>Forensic Science International</i> , 2007, 169, 168-172.	1.3	17
238	Vector-based RNAi approach to isoform-specific downregulation of vascular endothelial growth factor (VEGF) ₁₆₅ expression in human leukemia cells. <i>Leukemia Research</i> , 2007, 31, 515-521.	0.4	23
239	Targeting death-inducing receptors in cancer therapy. <i>Oncogene</i> , 2007, 26, 3745-3757.	2.6	178
240	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2007, 14, 133-139.	1.0	47
241	Imaging of angiogenesis in inflammation and cancer: lessons for novel treatment of allergic rhinitis. <i>Clinical and Experimental Allergy Reviews</i> , 2007, 7, 11-18.	0.3	4
242	The effect of old age on liver oxygenation and the hepatic expression of VEGF and VEGFR2. <i>Experimental Gerontology</i> , 2007, 42, 1012-1019.	1.2	20

#	ARTICLE	IF	CITATIONS
243	VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. <i>Experimental Cell Research</i> , 2007, 313, 1561-1574.	1.2	119
244	VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. <i>Experimental Cell Research</i> , 2007, 313, 3285-3297.	1.2	145
245	Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease. <i>Gynecologic Oncology</i> , 2007, 106, 513-520.	0.6	77
248	Expression of epidermal growth factor receptor (EGFR) is frequent in inflammatory bowel disease (IBD)-associated intestinal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 243-244.	1.4	22
249	Progress in defining the molecular biology of age related macular degeneration. <i>Human Genetics</i> , 2007, 122, 219-236.	1.8	64
250	Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years. <i>International Journal of Colorectal Disease</i> , 2007, 22, 855-862.	1.0	39
251	Vascular endothelial growth factors in pulmonary edema: an update. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 259-264.	1.0	29
252	Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells. <i>Investigational New Drugs</i> , 2008, 26, 215-222.	1.2	4
254	Connective tissue growth factor (CTGF) and cancer progression. <i>Journal of Biomedical Science</i> , 2008, 15, 675-685.	2.6	118
255	Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 – anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. <i>International Journal of Cancer</i> , 2008, 123, 1181-1189.	2.3	65
256	Antiangiogenic therapy and surgical practice. <i>British Journal of Surgery</i> , 2008, 95, 281-293.	0.1	9
257	Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5514-5528.	1.4	31
258	Regulation of ovarian angiogenesis and apoptosis by GnRH analogs. <i>Molecular Reproduction and Development</i> , 2008, 75, 623-631.	1.0	14
259	Trombo a3rtico debido a trombocitosis esencial: estrategias de tratamiento m3dico y4quir4rgico. <i>Annals of Vascular Surgery</i> , 2008, 22, 732-736.	0.0	0
260	The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. <i>Eye</i> , 2008, 22, 761-767.	1.1	40
261	Gefitinib (Iressa) Potentiates the Effect of Ionizing Radiation in Thyroid Cancer Cell Lines. <i>Laryngoscope</i> , 2008, 118, 1372-1376.	1.1	16
262	The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. <i>British Journal of Cancer</i> , 2008, 98, 1250-1257.	2.9	120
263	VEGF-A splicing: the key to anti-angiogenic therapeutics?. <i>Nature Reviews Cancer</i> , 2008, 8, 880-887.	12.8	440

#	ARTICLE	IF	CITATIONS
264	Cancer as an overhealing wound: an old hypothesis revisited. <i>Nature Reviews Molecular Cell Biology</i> , 2008, 9, 628-638.	16.1	779
265	Immunohistochemical evaluation of the microvascular density through the expression of TGF- β^2 (CD) Tj ETQq1 1 0.784314 rgBT /Over oligodendrogliomas. <i>Neuropathology</i> , 2008, 28, 17-23.	0.7	34
266	Targeting Slit- β Roundabout signaling inhibits tumor angiogenesis in chemical-induced squamous cell carcinogenesis. <i>Cancer Science</i> , 2008, 99, 510-517.	1.7	81
267	Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2008, 61, 82-90.	0.9	163
268	Grifola frondosa (Maitake Mushroom) Water Extract Inhibits Vascular Endothelial Growth Factor-Induced Angiogenesis Through Inhibition of Reactive Oxygen Species and Extracellular Signal-Regulated Kinase Phosphorylation. <i>Journal of Medicinal Food</i> , 2008, 11, 643-651.	0.8	27
269	Thrombose aortique due A une thrombocytose essentielle : stratÃ©gies de traitement mÃ©dical et chirurgical. <i>Annales De Chirurgie Vasculaire</i> , 2008, 22, 733-737.	0.0	0
270	Intravitreal Bevacizumab to Treat Iris Neovascularization and Neovascular Glaucoma Secondary to Ischemic Retinal Diseases in 41 Consecutive Cases. <i>Ophthalmology</i> , 2008, 115, 1571-1580.e3.	2.5	200
271	Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: A longitudinal study. <i>Transplant Immunology</i> , 2008, 18, 264-274.	0.6	16
272	Taspine downregulates VEGF expression and inhibits proliferation of vascular endothelial cells through PI3 kinase and MAP kinase signaling pathways. <i>Biomedicine and Pharmacotherapy</i> , 2008, 62, 383-389.	2.5	9
273	Showering c-MET-dependent cancers with drugs. <i>Current Opinion in Genetics and Development</i> , 2008, 18, 87-96.	1.5	131
274	Combination of Antiangiogenic Therapy with Other Anticancer Therapies. , 2008, , 431-449.		0
275	Chromosomes 7, 16 numerical aberrations are poor prognostic factors in colorectal adenocarcinoma: A tissue microarray analysis. <i>Basic and Applied Pathology</i> , 2008, 1, 125-130.	0.2	1
276	Aortic Thrombus due to Essential Thrombocytosis: Strategies for Medical and Surgical Management. <i>Annals of Vascular Surgery</i> , 2008, 22, 676-680.	0.4	14
278	Targeting cancer cells by synthetic lethality. <i>Cell Cycle</i> , 2008, 7, 2987-2990.	1.3	21
279	Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14082-14087.	3.3	453
280	Bevacizumab in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1559-1568.	1.1	19
281	Inhibitors of tumor angiogenesis. , 2008, , 351-381.		0
282	Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. <i>Journal of Leukocyte Biology</i> , 2008, 84, 561-576.	1.5	12

#	ARTICLE	IF	CITATIONS
283	Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3103-3111.	1.9	25
284	Potential Therapeutic Applications of miRNA-Based Technology in Hematological Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2040-2050.	0.9	23
285	Regulable Vascular Endothelial Growth Factor ¹⁶⁵ Overexpression by <i>Ex Vivo</i> Expanded Keratinocyte Cultures Promotes Matrix Formation, Angiogenesis, and Healing in Porcine Full-Thickness Wounds. <i>Tissue Engineering - Part A</i> , 2008, 14, 19-27.	1.6	19
286	Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells. <i>Growth Factors</i> , 2008, 26, 325-330.	0.5	21
287	Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. <i>Blood</i> , 2008, 111, 1594-1602.	0.6	70
288	A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies. <i>Current Pharmaceutical Design</i> , 2008, 14, 2085-2099.	0.9	16
289	TNF and manipulation of the tumor cell - stromal interface: "ways to make chemotherapy effective". <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 3034.	3.0	14
291	Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice. <i>World Journal of Gastroenterology</i> , 2009, 15, 5044.	1.4	23
292	Intravitreal Bevacizumab for the Treatment of Neovascular Glaucoma Associated With Central Retinal Artery Occlusion. <i>Korean Journal of Ophthalmology: KJO</i> , 2009, 23, 215.	0.5	9
293	Anti-angiogenic Drugs as an Adjunctive Therapy in the Surgical Treatment of Diabetic Retinopathy. <i>Current Diabetes Reviews</i> , 2009, 5, 52-56.	0.6	16
294	siRNA therapeutics for age-related macular degeneration: promises and pitfalls. <i>Expert Review of Ophthalmology</i> , 2009, 4, 525-535.	0.3	0
295	Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 2009, 20, 413-424.	0.6	86
296	Review Article: Targeted Therapy: Comprehensive Review. <i>American Journal of Hospice and Palliative Medicine</i> , 2009, 26, 137-146.	0.8	7
297	VEGFRs and Notch: a dynamic collaboration in vascular patterning. <i>Biochemical Society Transactions</i> , 2009, 37, 1233-1236.	1.6	140
298	Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. <i>Human Reproduction</i> , 2009, 24, 1025-1035.	0.4	107
299	Review: Adjuvant therapy for resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 109-118.	1.4	11
300	Target-based agents in neo-adjuvant treatment of liver metastases from colo-rectal cancer: Secret weapons in anticancer war?. <i>Cancer Biology and Therapy</i> , 2009, 8, 1709-1718.	1.5	3
301	Mode of action and clinical impact of VEGF signaling inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 649-662.	1.1	25

#	ARTICLE	IF	CITATIONS
302	Strategies to improve drug delivery in bladder cancer therapy. <i>Expert Opinion on Drug Delivery</i> , 2009, 6, 727-744.	2.4	19
303	Effect of radiation on vascular endothelial growth factor expression in the C2 canine mastocytoma cell line. <i>American Journal of Veterinary Research</i> , 2009, 70, 1141-1150.	0.3	6
304	The levels of vascular endothelial growth factor-A and placental growth factor-2 in embryopathy associated with experimental diabetic gestation. <i>Growth Factors</i> , 2009, 27, 32-39.	0.5	3
305	The preparation of radiolabeled monoclonal antibodies for human use. <i>Human Antibodies</i> , 2009, 18, 145-156.	0.6	4
306	Endogenous endothelial cell signaling systems maintain vascular stability. <i>Angiogenesis</i> , 2009, 12, 149-158.	3.7	56
307	The Tumor Microenvironment: The Making of a Paradigm. <i>Cancer Microenvironment</i> , 2009, 2, 9-17.	3.1	164
308	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2009, 145, 424-426.	1.2	2
309	Reduced expression of cell cycle-associated genes in B lymphocytes purified from the peripheral blood of early-stage B chronic lymphocytic leukaemia patients " response to di lasio <i>etAal</i>. <i>British Journal of Haematology</i> , 2009, 145, 426-428.	1.2	0
310	Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women. <i>Cell Proliferation</i> , 2009, 42, 506-510.	2.4	7
311	Dissociation between Vascular Endothelial Growth Factor Receptor-2 and Blood Vessel Density in the Caudate Nucleus after Chronic Hydrocephalus. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1806-1815.	2.4	14
312	Pyogenic granuloma complicating pulsed-dye laser therapy for cherry angioma. <i>Australasian Journal of Dermatology</i> , 2009, 50, 141-143.	0.4	6
313	Vascular dysfunction in the diabetic placenta: causes and consequences. <i>Journal of Anatomy</i> , 2009, 215, 69-76.	0.9	72
314	Human Studies of Angiogenic Gene Therapy. <i>Circulation Research</i> , 2009, 105, 724-736.	2.0	250
316	Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL. <i>Journal of Clinical Oncology</i> , 2009, 27, 1227-1234.	0.8	1,430
317	Microincision Vitrectomy Surgery and Intravitreal Bevacizumab as a Surgical Adjunct to Treat Diabetic Traction Retinal Detachment. <i>Ophthalmology</i> , 2009, 116, 927-938.	2.5	163
318	The dose-effectiveness of intranasal VEGF in treatment of experimental stroke. <i>Neuroscience Letters</i> , 2009, 461, 212-216.	1.0	49
319	Epidermal Growth Factor Receptor Activation Protects Gastric Epithelial Cells From Helicobacter pylori-Induced Apoptosis. <i>Gastroenterology</i> , 2009, 136, 1297-1307.e3.	0.6	98
320	VEGF inhibitors for the treatment of neovascular age-related macular degeneration. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 637-646.	1.9	53

#	ARTICLE	IF	CITATIONS
321	Adverse effects of anticancer agents that target the VEGF pathway. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 465-477.	12.5	492
322	Current status and future prospects for anti-angiogenic therapies in cancer. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 961-979.	2.5	24
323	Mechanisms of resistance to ionizing radiation in rectal cancer. <i>Expert Review of Molecular Diagnostics</i> , 2009, 9, 469-480.	1.5	36
325	Dusp-5 and Snrk-1 coordinately function during vascular development and disease. <i>Blood</i> , 2009, 113, 1184-1191.	0.6	91
326	Cooperative Signaling for Angiogenesis and Neovascularization by VEGF and HGF Following Islet Transplantation. <i>Transplantation</i> , 2010, 90, 725-731.	0.5	65
327	CYLD regulates angiogenesis by mediating vascular endothelial cell migration. <i>Blood</i> , 2010, 115, 4130-4137.	0.6	73
328	Heme oxygenase-1 in neovascularisation: A diabetic perspective. <i>Thrombosis and Haemostasis</i> , 2010, 104, 424-431.	1.8	35
329	xCT modulation in gliomas: Relevance to energy metabolism and tumor microenvironment normalization. <i>Annals of Anatomy</i> , 2010, 192, 309-313.	1.0	35
330	ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice. <i>Journal of Molecular Medicine</i> , 2010, 88, 497-505.	1.7	49
331	Stimulation of in vivo angiogenesis by in situ crosslinked, dual growth factor-loaded, glycosaminoglycan hydrogels. <i>Biomaterials</i> , 2010, 31, 4630-4638.	5.7	76
332	Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2010, 248, 785-791.	1.0	96
333	Molecular ultrasound assessment of tumor angiogenesis. <i>Angiogenesis</i> , 2010, 13, 175-188.	3.7	79
334	Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model. <i>Angiogenesis</i> , 2010, 13, 337-347.	3.7	15
335	Effect of mood stabilizers on gene expression in lymphoblastoid cells. <i>Journal of Neural Transmission</i> , 2010, 117, 155-164.	1.4	30
336	Loading of VEGF to the heparin cross-linked demineralized bone matrix improves vascularization of the scaffold. <i>Journal of Materials Science: Materials in Medicine</i> , 2010, 21, 309-317.	1.7	51
337	Cutaneous Angiomas in a Llama (<i>Lama glama</i>). <i>Journal of Comparative Pathology</i> , 2010, 142, 223-227.	0.1	7
338	A Phase II Trial of Docetaxel With Bevacizumab as First-line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). <i>Clinical Breast Cancer</i> , 2010, 10, 307-312.	1.1	12
339	The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. <i>BMC Cancer</i> , 2010, 10, 255.	1.1	130

#	ARTICLE	IF	CITATIONS
340	VEGF signaling is disrupted in the hearts of mice lacking estrogen receptor alpha. <i>European Journal of Pharmacology</i> , 2010, 641, 168-178.	1.7	24
341	The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3177-3181.	1.0	8
342	Alzheimer's β -amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR2. <i>Journal of Neurochemistry</i> , 2010, 112, 66-76.	2.1	84
343	De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. <i>Oncogene</i> , 2010, 29, 3411-3422.	2.6	142
344	Paeonol Oxime Inhibits bFGF-Induced Angiogenesis and Reduces VEGF Levels in Fibrosarcoma Cells. <i>PLoS ONE</i> , 2010, 5, e12358.	1.1	31
345	Systemic Propranolol Reduces b-Wave Amplitude in the ERG and Increases IGF-1 Receptor Phosphorylation in Rat Retina. , 2010, 51, 2730.		21
346	Role of omentum in wound healing of goats. <i>Bangladesh Veterinarian</i> , 2010, 25, 1-8.	0.4	1
347	Vascular endothelial growth factors and vascular permeability. <i>Cardiovascular Research</i> , 2010, 87, 262-271.	1.8	377
348	What Platelet Disorders Occur in the Intensive Care Unit and How Should They Be Treated?. , 2010, , 645-660.		0
349	Regulation of Vascular Endothelial Growth Factor Receptors by Rb and E2F1: Role of Acetylation. <i>Cancer Research</i> , 2010, 70, 4931-4940.	0.4	61
350	Protein kinase D2 is a crucial regulator of tumour cell-endothelial cell communication in gastrointestinal tumours. <i>Gut</i> , 2010, 59, 1316-1330.	6.1	68
351	ChIP-seq and Functional Analysis of the SOX2 Gene in Colorectal Cancers. <i>OMICS A Journal of Integrative Biology</i> , 2010, 14, 369-384.	1.0	61
352	Quantitation of angiogenesis in vitro induced by VEGF-A and FGF-2 in two different human endothelial cultures an all-in-one assay. <i>Clinical Hemorheology and Microcirculation</i> , 2010, 46, 189-202.	0.9	24
353	A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-11.	3.0	17
354	Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis. <i>Oncology</i> , 2010, 79, 27-38.	0.9	163
355	Heterogeneity of the Tumor Vasculature. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 321-331.	1.5	329
356	The Bcl-2 Family as a Rational Target for the Treatment of B-Cell Chronic Lymphocytic Leukaemia. <i>Current Medicinal Chemistry</i> , 2010, 17, 801-811.	1.2	15
357	Oncogenic KRAS Desensitizes Colorectal Tumor Cells to Epidermal Growth Factor Receptor Inhibition and Activation. <i>Neoplasia</i> , 2010, 12, 443-IN2.	2.3	42

#	ARTICLE	IF	CITATIONS
358	Role of Antibodies in Cancer Treatment (An Overview). , 2010, , 135-152.		3
359	Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. <i>Carcinogenesis</i> , 2010, 31, 1080-1086.	1.3	36
360	Bone marrow-derived cells are differentially involved in pathological and physiological retinal angiogenesis in mice. <i>Biochemical and Biophysical Research Communications</i> , 2010, 391, 1268-1273.	1.0	19
361	Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis. <i>Biochemical and Biophysical Research Communications</i> , 2010, 397, 729-734.	1.0	54
362	Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes. <i>Regulatory Peptides</i> , 2010, 160, 115-120.	1.9	17
363	Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2010, 69, S1-S3.	0.9	2
364	Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, S4-S10.	0.9	17
365	Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. <i>Lung Cancer</i> , 2010, 69, S11-S17.	0.9	26
366	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. <i>Lung Cancer</i> , 2010, 69, S18-S23.	0.9	10
367	Disparate Companions: Tissue Engineering Meets Cancer Research. <i>Cells Tissues Organs</i> , 2010, 192, 141-157.	1.3	6
368	RhoA Activation and Effect of Rho-kinase Inhibitor in the Development of Retinal Neovascularization in a Mouse Model of Oxygen-induced Retinopathy. <i>Current Eye Research</i> , 2011, 36, 1028-1036.	0.7	10
369	Apigenin Prevents Development of Medroxyprogesterone Acetate-Accelerated 7,12-Dimethylbenz(a)anthracene-Induced Mammary Tumors in Spragueâ€™Dawley Rats. <i>Cancer Prevention Research</i> , 2011, 4, 1316-1324.	0.7	35
370	Effects of Bevacizumab on Autocrine VEGF Stimulation in Bladder Cancer Cell Lines. <i>Urologia Internationalis</i> , 2011, 86, 95-101.	0.6	20
371	Microparticles in Angiogenesis. <i>Circulation Research</i> , 2011, 109, 110-119.	2.0	158
373	Effect of Vascular Endothelial Growth Factor Inhibition on Endometrial Implant Development in a Murine Model of Endometriosis. <i>Reproductive Sciences</i> , 2011, 18, 614-622.	1.1	88
374	Cisplatin, Irinotecan, and Bevacizumab for Untreated Extensive-Stage Small-Cell Lung Cancer: CALGB 30306, a Phase II Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4436-4441.	0.8	80
375	Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. <i>Steroids</i> , 2011, 76, 910-20.	0.8	65
376	Hematologic Disease. , 2011, , 261-280.		0

#	ARTICLE	IF	CITATIONS
377	Tumor-Surrogate Blood Vessel Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy. <i>Cancer Research</i> , 2011, 71, 7021-7028.	0.4	74
378	Angiogenesis and Lung Cancer. <i>Medical Radiology</i> , 2011, , 17-41.	0.0	1
379	Alternative angiogenic pathways in melanoma: the role of AQP1. <i>Journal of Solid Tumors</i> , 2011, 1, .	0.1	0
380	A Novel Peptide Derived from Human Apolipoprotein E Is an Inhibitor of Tumor Growth and Ocular Angiogenesis. <i>PLoS ONE</i> , 2011, 6, e15905.	1.1	24
381	Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011, 122, 495-500.	0.6	105
382	A functional and transcriptomic analysis of NET1 bioactivity in gastric cancer. <i>BMC Cancer</i> , 2011, 11, 50.	1.1	20
383	Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 19-26.	2.7	41
384	â€œClickâ€•Conjugation of Peptide on the Surface of Polymeric Nanoparticles for Targeting Tumor Angiogenesis. <i>Pharmaceutical Research</i> , 2011, 28, 1631-1642.	1.7	30
385	Treatment of collagen-induced arthritis with recombinant plasminogen-related protein B: a novel inhibitor of angiogenesis. <i>Journal of Orthopaedic Science</i> , 2011, 16, 443-450.	0.5	3
387	Emerging therapeutic approaches in the management of retinal angiogenesis and edema. <i>Journal of Molecular Medicine</i> , 2011, 89, 343-361.	1.7	25
388	Targetable â€œDriverâ€•Mutations in Non Small Cell Lung Cancer. <i>Indian Journal of Surgical Oncology</i> , 2011, 2, 178-188.	0.3	22
389	Minireview: Putting Physiology Back into Estrogens' Mechanism of Action. <i>Endocrinology</i> , 2011, 152, 4481-4488.	1.4	61
390	An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. <i>Current Medical Research and Opinion</i> , 2011, 27, 2193-2201.	0.9	3
391	Control of VEGF Expression in Triple-Negative Breast Carcinoma Cells by Suppression of <i>SAF-1</i> Transcription Factor Activity. <i>Molecular Cancer Research</i> , 2011, 9, 1030-1041.	1.5	25
392	Interactive Expressions of HtrA1 and VEGF in Human Vitreous Humors and Fetal RPE Cells. , 2011, 52, 3706.		18
393	Effect of Hedyotis Diffusa Willd extract on tumor angiogenesis. <i>Molecular Medicine Reports</i> , 2011, 4, 1283-8.	1.1	43
394	Insight into the role of microRNAs in brain tumors (Review). <i>International Journal of Oncology</i> , 2011, 40, 605-24.	1.4	10
395	Systemic Adverse Drug Reactions Secondary to Anti-VEGF Intravitreal Injection in Patients with Neovascular Age-Related Macular Degeneration. <i>Current Vascular Pharmacology</i> , 2011, 9, 629-646.	0.8	39

#	ARTICLE	IF	CITATIONS
397	Vascular endothelial growth factor expression in low and high grade b-cell non-hodgkin's lymphomas. <i>Turk Patoloji Dergisi</i> , 2011, 27, 204.	0.1	0
398	A Wound Size-Dependent Effect of Myeloid Cell-Derived Vascular Endothelial Growth Factor on Wound Healing. <i>Journal of Investigative Dermatology</i> , 2011, 131, 797-801.	0.3	39
399	Mitotic spindle (DIS)orientation and DISease: Cause or consequence?. <i>Journal of Cell Biology</i> , 2012, 199, 1025-1035.	2.3	94
400	A Comparative Study of the Fatty Acid Composition of Dairy Products and Margarines with Reduced or Substituted Fat Content. <i>Food and Nutrition Sciences (Print)</i> , 2012, 03, 1189-1196.	0.2	8
401	Design, Synthesis and Evaluation of Novel Benzimidazoles, Benzothiazoles and Benzofurans Incorporating Pyrazole Moiety as Antiangiogenic Agents. <i>Arzneimittelforschung</i> , 2012, 62, 63-74.	0.5	2
402	MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. <i>Oncogene</i> , 2012, 31, 3136-3147.	2.6	76
403	Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2012, 107, 598-603.	2.9	22
404	Vascular Endothelial Cell-specific MicroRNA-15a Inhibits Angiogenesis in Hindlimb Ischemia. <i>Journal of Biological Chemistry</i> , 2012, 287, 27055-27064.	1.6	122
405	Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer. <i>Oncologist</i> , 2012, 17, 469-475.	1.9	48
406	Chronic myeloproliferative disorders. , 0, , 444-502.		3
407	Noninvasive Infrared Imaging for Functional Monitoring of Disease Processes. , 2012, , 1-32.		0
408	Anti-tumor Activity of the Novel Hexahydrocannabinol Analog LYR-8 in Human Colorectal Tumor Xenograft Is Mediated through the Inhibition of Akt and Hypoxia-Inducible Factor-1 α Activation. <i>Biological and Pharmaceutical Bulletin</i> , 2012, 35, 924-932.	0.6	14
409	North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane. <i>Clinical Breast Cancer</i> , 2012, 12, 387-391.	1.1	22
410	The Effect of Bevacizumab on Human Malignant Melanoma Cells with Functional VEGF/VEGFR2 Autocrine and Intracrine Signaling Loops. <i>Neoplasia</i> , 2012, 14, 612-IN16.	2.3	43
411	Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 657-662.	1.7	130
412	Mucin 1 enhances the tumor angiogenic response by activation of the AKT signaling pathway. <i>Oncogene</i> , 2012, 31, 2187-2198.	2.6	57
413	The influence of fundamental traits on mechanisms controlling appendage regeneration. <i>Biological Reviews</i> , 2012, 87, 330-345.	4.7	64
414	Expression of therapeutic targets in Ewing sarcoma family tumors. <i>Human Pathology</i> , 2012, 43, 1077-1083.	1.1	17

#	ARTICLE	IF	CITATIONS
415	A Customized Self-Assembling Peptide Hydrogel for Dental Pulp Tissue Engineering. <i>Tissue Engineering - Part A</i> , 2012, 18, 176-184.	1.6	233
416	A novel treatment for glioblastoma: integrin inhibition. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 421-435.	1.4	34
417	Anti-angiogenic activity of thymoquinone by the down-regulation of VEGF using zebrafish (<i>Danio</i>) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.9	18
418	Clinical Correlations and Prognostic Relevance of Tissue Angiogenic Factors in Patients with Gastric Cancer. <i>Clinical Oncology</i> , 2012, 24, 610-616.	0.6	6
419	An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. <i>Lung Cancer</i> , 2012, 78, 1-7.	0.9	43
420	Effects of Pien Tze Huang (ç%«†ä»”ç™€) on angiogenesis in vivo and in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2012, 18, 431-436.	0.7	35
421	VEGF Improves Skeletal Muscle Regeneration After Acute Trauma and Reconstruction of the Limb in a Rabbit Model. <i>Clinical Orthopaedics and Related Research</i> , 2012, 470, 3607-3614.	0.7	51
422	Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma. <i>Acta Oto-Laryngologica</i> , 2012, 132, 574-582.	0.3	44
423	Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration. <i>Journal of Ophthalmology</i> , 2012, 2012, 1-12.	0.6	39
424	Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity. <i>International Journal of Nanomedicine</i> , 2012, 7, 5259.	3.3	30
425	Mucosal Restitution and Repair. , 2012, , 1147-1168.		4
426	Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 620-626.	0.7	18
427	VEGF is essential for the growth and migration of human hepatocellular carcinoma cells. <i>Molecular Biology Reports</i> , 2012, 39, 5085-5093.	1.0	75
428	c-ABL modulates MAP kinases activation downstream of VEGFR-2 signaling by direct phosphorylation of the adaptor proteins GRB2 and NCK1. <i>Angiogenesis</i> , 2012, 15, 187-197.	3.7	31
429	Effect of topical application of mitomycin-C on wound healing in a postlaminectomy rat model: An experimental study. <i>European Journal of Pharmacology</i> , 2012, 674, 7-12.	1.7	31
430	Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 439-446.	1.1	24
431	Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. <i>Angiogenesis</i> , 2012, 15, 1-22.	3.7	116
432	VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 363-370.	1.2	80

#	ARTICLE	IF	CITATIONS
433	Vascular-targeted therapies for Duchenne muscular dystrophy. <i>Skeletal Muscle</i> , 2013, 3, 9.	1.9	41
434	Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study. <i>Clinical and Translational Oncology</i> , 2013, 15, 953-958.	1.2	9
435	In vivo characterization of ⁶⁸ Ga-NOTA-VEGF121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 198-206.	3.3	19
436	Therapeutic angiogenesis for revascularization in peripheral artery disease. <i>Gene</i> , 2013, 525, 220-228.	1.0	85
437	Bilateral internal carotid arteries ligation temporary impairs brain vasculature in young rats. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 173, 39-44.	1.4	6
438	Increase of Epidermal Growth Factor Receptor Expression in Progression of GERD, Barrett, and Adenocarcinoma of Esophagus. <i>Digestive Diseases and Sciences</i> , 2013, 58, 115-122.	1.1	8
439	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. <i>Taiwan Journal of Ophthalmology</i> , 2013, 3, 128-133.	0.3	3
440	A novel plasmid and SonoVue formulation plus ultrasound sonication for effective gene delivery in nude mice. <i>Life Sciences</i> , 2013, 93, 536-542.	2.0	8
441	N ² -Trimethylacetyl substituted and unsubstituted-N ⁴ -phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: Design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 1312-1323.	1.4	11
442	Age-Related Macular Degeneration. <i>Pharmacotherapy</i> , 2013, 33, 838-855.	1.2	95
443	A SIEVE-RAFT HYPOTHESIS FOR THE REGULATION OF ENDOTHELIAL FENESTRATIONS. <i>Computational and Structural Biotechnology Journal</i> , 2013, 8, e201308003.	1.9	21
444	<i>Patrinia scabiosaefolia</i> inhibits colorectal cancer growth through suppression of tumor angiogenesis. <i>Oncology Reports</i> , 2013, 30, 1439-1443.	1.2	27
445	Epithelial Membrane Protein 2 Controls VEGF Expression in ARPE-19 Cells. , 2013, 54, 2367.		15
446	Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in Increasing Vascular Endothelial Growth Factor (VEGF) Expression in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2013, 288, 27232-27242.	1.6	35
447	Studies on the anti-angiogenic effect of <i>Marsdenia tenacissima</i> extract in vitro and in vivo. <i>Oncology Letters</i> , 2013, 5, 917-922.	0.8	36
448	Blockade of NF- κ B nuclear translocation results in the inhibition of the invasiveness of human gastric cancer cells. <i>Oncology Letters</i> , 2013, 6, 432-436.	0.8	9
449	<i>Hedyotis diffusa</i> Willd extract suppresses Sonic hedgehog signaling leading to the inhibition of colorectal cancer angiogenesis. <i>International Journal of Oncology</i> , 2013, 42, 651-656.	1.4	56
450	Pien Tze Huang inhibits tumor angiogenesis in a mouse model of colorectal cancer via suppression of multiple cellular pathways. <i>Oncology Reports</i> , 2013, 30, 1701-1706.	1.2	33

#	ARTICLE	IF	CITATIONS
451	Convergent RANK- and c-Met-Mediated Signaling Components Predict Survival of Patients with Prostate Cancer: An Interracial Comparative Study. <i>PLoS ONE</i> , 2013, 8, e73081.	1.1	14
452	Inhibition of Angiogenesis Mediated by Extremely Low-Frequency Magnetic Fields (ELF-MFs). <i>PLoS ONE</i> , 2013, 8, e79309.	1.1	44
453	Current Treatment Limitations in Age-Related Macular Degeneration and Future Approaches Based on Cell Therapy and Tissue Engineering. <i>Journal of Ophthalmology</i> , 2014, 2014, 1-13.	0.6	53
454	Aflibercept for diabetic macular edema. <i>Expert Review of Ophthalmology</i> , 2014, 9, 263-268.	0.3	0
455	Advanced Age Impairs Cardioprotective Function of Mesenchymal Stem Cell Transplantation from Patients to Myocardially Infarcted Rats. <i>Cardiology</i> , 2014, 128, 209-219.	0.6	11
456	TM4SF1: a new vascular therapeutic target in cancer. <i>Angiogenesis</i> , 2014, 17, 897-907.	3.7	36
457	Isolation of equine endothelial cells and life cell angiogenesis assay. <i>Clinical Hemorheology and Microcirculation</i> , 2014, 58, 127-146.	0.9	9
458	Epidermal growth factor receptor signaling pathway is frequently altered in ampullary carcinoma at protein and genetic levels. <i>Modern Pathology</i> , 2014, 27, 665-674.	2.9	29
459	Expression of vascular endothelial growth factor and hypoxia-inducible factor-1 alpha during the periovulatory period in goats. <i>Turkish Journal of Veterinary and Animal Sciences</i> , 2014, 38, 699-706.	0.2	5
460	Cancer cell-associated fatty acid synthase activates endothelial cells and promotes angiogenesis in colorectal cancer. <i>Carcinogenesis</i> , 2014, 35, 1341-1351.	1.3	80
461	Sunitinib malate in the treatment of urothelial cancer. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 115-124.	1.9	4
462	Sustained Delivery of VEGF Maintains Innervation and Promotes Reperfusion in Ischemic Skeletal Muscles Via NGF/GDNF Signaling. <i>Molecular Therapy</i> , 2014, 22, 1243-1253.	3.7	77
463	Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta-analysis of 36 clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 748-762.	1.1	81
464	Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells. <i>Cancer Gene Therapy</i> , 2014, 21, 275-282.	2.2	8
465	Molecular-targeted Therapy for Renal Cell Carcinoma. , 2014, , 115-127.		3
466	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	1.1	10
467	The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. <i>British Journal of Haematology</i> , 2014, 165, 78-88.	1.2	5
468	Inhibitors of Tumor Angiogenesis. , 2014, , 275-317.		1

#	ARTICLE	IF	CITATIONS
469	Dual Delivery of Vascular Endothelial Growth Factor and Hepatocyte Growth Factor Coacervate Displays Strong Angiogenic Effects. <i>Macromolecular Bioscience</i> , 2014, 14, 679-686.	2.1	52
470	Increased levels of exhaled sICAM1, sVCAM1, and sE-selectin in patients with non-small cell lung cancer. <i>Respiratory Medicine</i> , 2014, 108, 1670-1676.	1.3	17
471	Complications of Subspecialty Ophthalmic Care: Systemic Complications from the Intravitreal Administration of Agents that Target the Vascular Endothelial Growth Factor Pathway. <i>Seminars in Ophthalmology</i> , 2014, 29, 263-275.	0.8	9
472	Comparative insight into expression of recombinant human VEGF111b, a newly identified anti-angiogenic isoform, in eukaryotic cell lines. <i>Gene</i> , 2014, 553, 57-62.	1.0	3
473	Autocrine Impact of VEGF-A on Uveal Melanoma Cells. , 2014, 55, 2697.		20
474	Advances in the approach to novel drug clinical development for breast cancer. <i>Expert Opinion on Drug Discovery</i> , 2014, 9, 647-668.	2.5	6
475	Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 1-18.	1.0	44
476	Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib. <i>Leukemia Research</i> , 2014, 38, 662-665.	0.4	15
477	Apigenin inhibits TGF- β -induced VEGF expression in human prostate carcinoma cells via a Smad2/3- and Src-dependent mechanism. <i>Molecular Carcinogenesis</i> , 2014, 53, 598-609.	1.3	58
478	Neutralization of ADAM8 ameliorates liver injury and accelerates liver repair in carbon tetrachloride-induced acute liver injury. <i>Journal of Toxicological Sciences</i> , 2014, 39, 339-351.	0.7	11
479	Qianliening capsule inhibits benign prostatic hyperplasia angiogenesis via the HIF-1 α signaling pathway. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 118-124.	0.8	9
480	Suppression of VEGF expression through interruption of the HIF-1 α and Akt signaling cascade modulates the anti-angiogenic activity of DAPK in ovarian carcinoma cells. <i>Oncology Reports</i> , 2014, 31, 1021-1029.	1.2	20
481	<i>Livistona chinensis</i> seeds inhibit hepatocellular carcinoma angiogenesis in vivo via suppression of the Notch pathway. <i>Oncology Reports</i> , 2014, 31, 1723-1728.	1.2	21
482	Tumor Stroma, Tumor Blood Vessels, and Antiangiogenesis Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 237-243.	1.0	90
483	Induction of Ras by SAF β /MAZ through a feed-forward loop promotes angiogenesis in breast cancer. <i>Cancer Medicine</i> , 2015, 4, 224-234.	1.3	25
484	Blockade of vascular endothelial growth factor-A/receptor 2 exhibits a protective effect on angiotensin-II stimulated podocytes. <i>Molecular Medicine Reports</i> , 2015, 12, 4340-4345.	1.1	14
485	Identification of Natural Protein-Protein Interactions with cDNA Libraries. , 2015, , 312-327.		1
486	Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. <i>Oncology Letters</i> , 2015, 9, 2577-2582.	0.8	3

#	ARTICLE	IF	CITATIONS
487	Tumor Necrosis Factor- α -Induced Protein-8 Like-2 (TIPE2) Upregulates p27 to Decrease Gastric Cancer Cell Proliferation. <i>Journal of Cellular Biochemistry</i> , 2015, 116, 1121-1129.	1.2	43
488	Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. , 2015, 56, 5691.		16
489	Effects of Tetrahydrocurcumin on Hypoxia-Inducible Factor-1 and Vascular Endothelial Growth Factor Expression in Cervical Cancer Cell-Induced Angiogenesis in Nude Mice. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	26
490	Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug. <i>PLoS ONE</i> , 2015, 10, e0140011.	1.1	31
491	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose. <i>PLoS ONE</i> , 2015, 10, e0143941.	1.1	17
492	The potential of targeted antiangiogenesis therapies in the treatment of esophageal cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 0, , 79.	5.5	1
493	Production of Novel VHH Nanobody Inhibiting Angiogenesis by Targeting Binding Site of VEGF. <i>Applied Biochemistry and Biotechnology</i> , 2015, 176, 1985-1995.	1.4	29
494	Total alkaloids of <i>Rubus alceifolius</i> Poir inhibit tumor angiogenesis through suppression of the Notch signaling pathway in a mouse model of hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2015, 11, 357-361.	1.1	10
495	Cyclic Adenosine Monophosphate-Mediated Enhancement of Vascular Endothelial Growth Factor Released by Differentiated Human Monocytic Cells: The Role of Protein Kinase A. <i>Medical Principles and Practice</i> , 2015, 24, 548-554.	1.1	7
496	The important role of ADAM8 in the progression of hepatocellular carcinoma induced by diethylnitrosamine in mice. <i>Human and Experimental Toxicology</i> , 2015, 34, 1053-1072.	1.1	6
497	Monoclonal Antibodies for Cancer Immunotherapy. , 2015, , 293-328.		6
498	Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3) stabilizes hypoxia inducible factor-1 alpha, promotes neovascularization, and improves perfusion in a murine model of hind-limb ischemia. <i>Microvascular Research</i> , 2015, 97, 181-188.	1.1	27
499	Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1868-1876.	1.9	31
500	Second malignancies in patients with primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2015, 17, 129-135.	0.6	4
501	Bear bile powder inhibits angiogenesis in vivo and in vitro. <i>Chinese Journal of Integrative Medicine</i> , 2015, 21, 369-375.	0.7	7
502	The Effect of Hydroxycamptothecin on Wound Healing Following Reduction of the Knee Intra-Articular Adhesion in Rabbits. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 221-227.	0.9	10
503	Bevacizumab in combination with anticancer drugs for previously treated advanced non-small cell lung cancer. <i>Tumor Biology</i> , 2015, 36, 1323-1327.	0.8	8
505	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1614-1624.	1.9	85

#	ARTICLE	IF	CITATIONS
506	Interplay between receptor tyrosine kinases and hypoxia signaling in cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2015, 62, 101-114.	1.2	23
507	Inhibition of human placental endothelial cell proliferation and angiogenesis by netrin-4. <i>Placenta</i> , 2015, 36, 1260-1265.	0.7	16
508	Identification of inhibitors that target dual-specificity phosphatase 5 provide new insights into the binding requirements for the two phosphate pockets. <i>BMC Biochemistry</i> , 2015, 16, 19.	4.4	8
509	Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. <i>Oncologist</i> , 2015, 20, 952-959.	1.9	23
510	Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2876-2882.	0.6	13
511	Surfactant-based drug delivery systems for treating drug-resistant lung cancer. <i>Drug Delivery</i> , 2016, 23, 717-728.	2.5	63
512	Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases. <i>Current Angiogenesis</i> , 2016, 4, 24-36.	0.1	0
513	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4639-4644.	1.0	6
514	Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review. <i>OncoTargets and Therapy</i> , 2016, 9, 3695.	1.0	12
515	Association between Vascular Endothelial Growth Factor Gene Polymorphisms with Breast Cancer Risk in an Iranian Population. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S39649.	0.6	22
516	The role of semaphorin 4D as a potential biomarker for antiangiogenic therapy in colorectal cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 1189.	1.0	11
517	Astrocytes spatially restrict VEGF signaling by polarized secretion and incorporation of VEGF into the actively assembling extracellular matrix. <i>Glia</i> , 2016, 64, 440-456.	2.5	18
518	MARCKSL1 exhibits anti-angiogenic effects through suppression of VEGFR-2-dependent Akt/PDK-1/mTOR phosphorylation. <i>Oncology Reports</i> , 2016, 35, 1041-1048.	1.2	14
519	Clinicopathologic characteristics and survival of patients with gynecologic malignancies metastatic to the brain. <i>Gynecologic Oncology</i> , 2016, 142, 76-82.	0.6	26
520	TIP2, a negative regulator of TLR signaling, regulates p27 through IRF4-induced signaling. <i>Oncology Reports</i> , 2016, 35, 2480-2486.	1.2	15
521	The Potential of Combination Therapeutics for More Complete Repair of Volumetric Muscle Loss Injuries: The Role of Exogenous Growth Factors and/or Progenitor Cells in Implantable Skeletal Muscle Tissue Engineering Technologies. <i>Cells Tissues Organs</i> , 2016, 202, 202-213.	1.3	25
522	Fatal hemorrhage in a patient with advanced soft tissue sarcoma following radiation and pazopanib treatment: A case report. <i>Oncology Letters</i> , 2016, 11, 2408-2410.	0.8	8
523	NG2 Proteoglycan-Dependent Contributions of Pericytes and Macrophages to Brain Tumor Vascularization and Progression. <i>Microcirculation</i> , 2016, 23, 122-133.	1.0	38

#	ARTICLE	IF	CITATIONS
524	INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. <i>Retina</i> , 2016, 36, 938-943.	1.0	63
525	Establishment of a new animal model of azithromycin-induced liver injury and study the molecular pathological change during the process. <i>Human and Experimental Toxicology</i> , 2016, 35, 511-525.	1.1	6
526	Altered astrocyte morphology and vascular development in dystrophin Δ mice. <i>Glia</i> , 2016, 64, 716-729.	2.5	20
527	Melittin suppresses cathepsin S-induced invasion and angiogenesis via blocking of the VEGF-A/VEGFR-2/MEK1/ERK1/2 pathway in human hepatocellular carcinoma. <i>Oncology Letters</i> , 2016, 11, 610-618.	0.8	43
528	Tumor Blood Vessels and Tumor Endothelial Cells. , 2016, , 11-18.		0
529	The Role of Microenvironment in the Control of Tumor Angiogenesis. , 2016, , .		3
530	Progesterone amplifies oxidative stress signal and promotes NO production via H ₂ O ₂ in mouse kidney arterial endothelial cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 104-111.	1.2	23
531	Pharmacotherapy for treating metastatic clear cell renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 205-216.	0.9	5
532	Vascular endothelial growth factor suppresses TNFSF15 production in endothelial cells by stimulating miR-31 and miR-20a expression via activation of Akt and Erk signals. <i>FEBS Open Bio</i> , 2017, 7, 108-117.	1.0	23
533	Endothelial cell markers from clinician's perspective. <i>Experimental and Molecular Pathology</i> , 2017, 102, 303-313.	0.9	68
534	Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. <i>Drug Safety</i> , 2017, 40, 1131-1140.	1.4	24
535	MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. <i>Oncogene</i> , 2017, 36, 3986-4000.	2.6	118
536	Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. <i>International Journal of Cancer</i> , 2017, 140, 2183-2191.	2.3	33
537	Contribution of neuroblastoma-derived exosomes to the production of pro-tumorigenic signals by bone marrow mesenchymal stromal cells. <i>Journal of Extracellular Vesicles</i> , 2017, 6, 1332941.	5.5	47
538	The major thoracic vascular invasion of lung cancer. <i>Annals of Medicine and Surgery</i> , 2017, 20, 13-18.	0.5	5
539	Anti-angiogenic effect of <i>Livistona chinensis</i> seed extract in vitro and in vivo. <i>Oncology Letters</i> , 2017, 14, 7565-7570.	0.8	7
540	Expression pattern of HIF1 α and vasohibins during follicle maturation and corpus luteum function in the bovine ovary. <i>Reproduction in Domestic Animals</i> , 2017, 52, 130-139.	0.6	21
541	Adeno-associated virus serotype 9 mediated vascular endothelial growth factor gene overexpression in mdx mice. <i>Experimental and Therapeutic Medicine</i> , 2017, 15, 1825-1830.	0.8	5

#	ARTICLE	IF	CITATIONS
542	Protective role of microRNA-126 in intracerebral hemorrhage. <i>Molecular Medicine Reports</i> , 2017, 15, 1419-1425.	1.1	26
543	Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway. <i>PLoS ONE</i> , 2017, 12, e0186520.	1.1	57
544	Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema: a real-life clinical practice study. <i>BMC Ophthalmology</i> , 2017, 17, 158.	0.6	38
545	Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials. <i>Nanotheranostics</i> , 2017, 1, 346-357.	2.7	76
546	Antioxidant properties of <i>Artemisia absinthium</i> accelerate healing of experimental Achilles tendon injury in rabbits. <i>Herba Polonica</i> , 2018, 64, 36-43.	0.2	4
547	Expression of vascular endothelial growth factor and its correlation with clinical symptoms and endoscopic findings in patients with chronic radiation proctitis. <i>Colorectal Disease</i> , 2018, 20, 321-330.	0.7	5
548	The Neuropilins and Their Ligands in Hematogenous Metastasis of Salivary Adenoid Cystic Carcinoma—An Immunohistochemical Study. <i>Journal of Oral and Maxillofacial Surgery</i> , 2018, 76, 569-579.	0.5	9
549	Mediators of angiogenesis and fibrosis in IgG4-related disease. <i>Clinical and Experimental Medicine</i> , 2018, 18, 245-249.	1.9	4
550	Cetirizine and thalidomide synergistically inhibit mammary tumorigenesis and angiogenesis in 7,12-dimethylbenz(a)anthracene-treated rats. <i>Anti-Cancer Drugs</i> , 2018, 29, 956-964.	0.7	2
551	Loss of Multimerin-2 and EMILIN-2 Expression in Gastric Cancer Associate with Altered Angiogenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3983.	1.8	26
552	A 2D mathematical model for tumor angiogenesis: The roles of certain cells in the extra cellular matrix. <i>Mathematical Biosciences</i> , 2018, 306, 32-48.	0.9	4
553	A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy. <i>Lasers in Surgery and Medicine</i> , 2018, 50, 440-450.	1.1	13
554	Pigmented purpura and cutaneous vascular occlusion syndromes. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 397-404.	0.5	14
555	Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. <i>Science Signaling</i> , 2019, 12, .	1.6	83
556	The endothelial tip-stalk cell selection and shuffling during angiogenesis. <i>Journal of Cell Communication and Signaling</i> , 2019, 13, 291-301.	1.8	85
557	Healing potential of injectable Aloe vera hydrogel loaded by adipose-derived stem cell in skin tissue-engineering in a rat burn wound model. <i>Cell and Tissue Research</i> , 2019, 377, 215-227.	1.5	55
558	Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer. <i>Nature Communications</i> , 2019, 10, 720.	5.8	57
559	Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. <i>Egyptian Journal of Medical Human Genetics</i> , 2019, 20, .	0.5	62

#	ARTICLE	IF	CITATIONS
560	Immune checkpoint inhibitors in gastrointestinal malignancies: what can we learn from experience with other tumors?. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 73-73.	1.5	4
561	Expression of a functional recombinant vascular endothelial growth factor 165 (VEGF ₁₆₅) in <i>Arabidopsis thaliana</i> . <i>Biyokimya Dergisi</i> , 2019, 44, 254-260.	0.1	2
562	Vitreous concentrations of vascular endothelial growth factor as a potential biomarker for postoperative complications following pars plana vitrectomy. <i>Archives of Medical Science</i> , 2019, 15, 449-456.	0.4	6
563	Anti-angiogenic isoform of vascular endothelial growth factor-A in cardiovascular and renal disease. <i>Advances in Clinical Chemistry</i> , 2019, 88, 1-33.	1.8	21
564	Retinal and choroidal cancers: Blood-retinal barriers considerations in ocular chemotherapy. , 2020, , 303-335.		4
565	Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 via AKT. <i>Cancer Biology and Therapy</i> , 2020, 21, 354-363.	1.5	18
566	Ablation of neuropilin-1 improves the therapeutic response in conventional drug-resistant glioblastoma multiforme. <i>Oncogene</i> , 2020, 39, 7114-7126.	2.6	17
567	Hydrogels and Dentinâ€™Pulp Complex Regeneration: From the Benchtop to Clinical Translation. <i>Polymers</i> , 2020, 12, 2935.	2.0	44
568	Tramadol: a Potential Neurotoxic Agent Affecting Prefrontal Cortices in Adult Male Rats and PC-12 Cell Line. <i>Neurotoxicity Research</i> , 2020, 38, 385-397.	1.3	16
569	Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. <i>Acta Ophthalmologica</i> , 2020, 98, e1004-e1008.	0.6	20
570	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 221.	1.3	213
572	Targeting MDRâ€™1 gene expression, BAX/BCL2, caspaseâ€™3, and Kiâ€™67 by nanoencapsulated imatinib and hesperidin to enhance anticancer activity and ameliorate cardiotoxicity. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 458-475.	1.0	24
573	Enhanced anticancer activity of combined treatment of imatinib and dipyridamole in solid Ehrlich carcinoma-bearing mice. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 1113-1129.	1.4	3
574	Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. <i>Frontiers in Pharmacology</i> , 2020, 11, 315.	1.6	9
575	Scar-reducing effects of gambogic acid on skin wounds in rabbit ears. <i>International Immunopharmacology</i> , 2021, 90, 107200.	1.7	7
576	The antiâ€™adhesive effect of <sc>antiâ€™VEGF</sc> agents in experimental models: A systematic review. <i>Wound Repair and Regeneration</i> , 2021, 29, 168-182.	1.5	1
577	Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin/utrophin double knockout mice. <i>Human Molecular Genetics</i> , 2021, 30, 1349-1359.	1.4	6
578	Local administration of allogeneic or autologous bone marrow-derived mesenchymal stromal cells enhances bone formation similarly in distraction osteogenesis. <i>Cytherapy</i> , 2021, 23, 590-598.	0.3	9

#	ARTICLE	IF	CITATIONS
579	Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches. Expert Opinion on Investigational Drugs, 2021, 30, 947-963.	1.9	11
580	Novel Molecule Nell-1 Promotes the Angiogenic Differentiation of Dental Pulp Stem Cells. Frontiers in Physiology, 2021, 12, 703593.	1.3	2
581	Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. Annals of Translational Medicine, 2021, 9, 1285-1285.	0.7	3
582	Current Management of Age-Related Macular Degeneration. Advances in Experimental Medicine and Biology, 2021, 1256, 295-314.	0.8	6
583	Clinical Development of VEGF Trap. , 2008, , 415-420.		2
584	Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature. , 2013, , 241-254.		1
585	Oncogenes and Tumor Suppressor Genes in Therapeutic Resistance. , 2006, , 67-103.		1
586	The Role of Lymphangiogenesis in Regional Lymph Node Metastasis: Animal Models. , 2009, , 211-226.		1
587	Vascular Endothelial Growth Factor. , 2008, , 395-423.		5
588	Molecular Signaling Pathways in Nasopharyngeal Cancer. Medical Radiology, 2010, , 27-40.	0.0	2
589	Invasion as limitation to anti-angiogenic glioma therapy. , 2003, 88, 169-177.		122
590	Etiologic Mechanisms in Diabetic Retinopathy. , 2006, , 1241-1270.		23
591	Vitamin D and Cardiovascular Medicine. , 2005, , 899-910.		3
592	Modulation of angiogenesis in patients with myelodysplastic syndrome. Best Practice and Research in Clinical Haematology, 2004, 17, 623-639.	0.7	10
593	Angiogenesis pathway inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, 22, 225-245.	0.5	2
594	Out of air is not out of action. , 0, .		1
595	Bevacizumab-associated hypertension: etiology, incidence, and management. Anti-Cancer Drugs, 2009, 20, S22-S24.	0.7	2
596	A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors. Journal of Thoracic Oncology, 2006, 1, 1002-1009.	0.5	115

#	ARTICLE	IF	CITATIONS
597	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. <i>Journal of Clinical Investigation</i> , 2003, 111, 1287-1295.	3.9	560
598	Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. <i>Journal of Clinical Investigation</i> , 2003, 111, 1287-1295.	3.9	1,107
599	Infrared Imaging for Functional Monitoring of Disease Processes. , 2007, , 14-1-14-28.		2
600	Genetic Variants of EGF and VEGF Predict Prognosis of Patients with Advanced Esophageal Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e100326.	1.1	30
601	Tumor suppressive effects of the pleiotropically acting miR-195 in colorectal cancer cells. <i>EXCLI Journal</i> , 2019, 18, 243-252.	0.5	8
602	Suppression of vascular endothelial growth factor expression in breast cancer cells by microRNA-125b-mediated attenuation of serum amyloid A activating factor-1 level. <i>Oncoscience</i> , 2019, 6, 337-348.	0.9	5
603	A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. <i>Oncotarget</i> , 2015, 6, 22750-22757.	0.8	7
604	Chronic Inflammation and Radiation-Induced Cystitis: Molecular Background and Therapeutic Perspectives. <i>Cells</i> , 2021, 10, 21.	1.8	24
605	Synthesis of ribozyme against vascular endothelial growth factor165 and its biological activity in vitro. <i>World Journal of Gastroenterology</i> , 2004, 10, 1495.	1.4	3
606	Hepatic artery infusion of antisense oligodeoxynucleotide and lipiodol mixture transfect liver cancer in rats. <i>World Journal of Gastroenterology</i> , 2005, 11, 2408.	1.4	5
607	Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor. <i>World Journal of Gastroenterology</i> , 2005, 11, 5032.	1.4	11
608	Molecule action mechanisms of NM-3 on human gastric cancer SGC-7901 cells in vivo or in vitro. <i>World Journal of Gastroenterology</i> , 2003, 9, 2366.	1.4	8
609	Treatment of Neovascular Age-Related Macular Degeneration with Pegaptanib and Boosting with Bevacizumab or Ranibizumab as Needed. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2008, 39, 294-298.	0.4	7
610	^{99m} Tc-Labeled Bevacizumab via HYNIC for Imaging of Melanoma. <i>Journal of Analytical Oncology</i> , 2014, 3, .	0.1	5
611	Role of +405C>G and +936C>T Polymorphisms of the Vascular Endothelial Growth Factor Gene and Risk of Esophageal Cancer in the Kashmiri Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 97-101.	0.5	5
612	TRANSPLANTATION OF SATELLITE CELLS FOR MYOCARDIAL REGENERATION. , 2003, , 102-115.		0
613	VEGF-F14šé«~ã,é,æŠžæ€šã*ã¼·ãŠ>ã*ç”Ýç%©æ´»æ€šã,æ€šãf~ãf“æ´ç”±æ¥ã®æ-°ã-ã,VEGF. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2003, 83, 102-115.		0
614	Regulation of Postangiogenic Vascular Regression. , 2006, , 79-95.		0

#	ARTICLE	IF	CITATIONS
636	Gene Therapy for Neovascular Retinopathies. , 2006, , 355-371.		0
637	Clinical Development of Sorafenib (BAY 439006) VEGFR and RAF Inhibitor. , 2008, , 655-671.		1
638	The Role of the Neuropilins and Their Associated Plexin Receptors in Tumor Angiogenesis and Tumor Progression. , 2008, , 135-153.		0
640	Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia, 2004, 6, 248-57.	2.3	47
641	VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. Journal of Experimental Therapeutics and Oncology, 2008, 7, 89-97.	0.5	7
642	Antiangiogenic agents in first-line and second-line therapy for advanced colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, S22-8.	0.8	0
643	Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization. Molecular Vision, 2010, 16, 1743-53.	1.1	10
644	Angiogenesis and melanoma - from basic science to clinical trials. American Journal of Cancer Research, 2011, 1, 852-68.	1.4	21
645	Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium. Molecular Vision, 2012, 18, 519-27.	1.1	28
646	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. American Journal of Translational Research (discontinued), 2013, 5, 393-403.	0.0	21
647	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. Translational Lung Cancer Research, 2013, 2, E13-6.	1.3	0
648	Angiogenesis, cell differentiation and cell survival in tissue engineering and cancer research. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2015, 4, Doc08.	0.1	4
649	The effect of butyric acid with autogenous omental graft on healing of experimental Achilles tendon injury in rabbits. Iranian Journal of Veterinary Research, 2015, 16, 100-4.	0.4	2
650	Roundabout1 distribution in neoplastic and non-neoplastic diseases with a focus on neoangiogenesis. International Journal of Clinical and Experimental Pathology, 2018, 11, 5755-5764.	0.5	3
651	Relation Between Telomere and Reactive Oxygen Species in Angiogenesis. Proceedings of the National Academy of Sciences India Section B - Biological Sciences, 0, , 1.	0.4	0
652	Dysregulated Serum Lipid Metabolism Promotes the Occurrence and Development of Diabetic Retinopathy Associated With Upregulated Circulating Levels of VEGF-A, VEGF-D, and PlGF. Frontiers in Medicine, 2021, 8, 779413.	1.2	17
653	Targeting VEGFR α 2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Archiv Der Pharmazie, 2021, , e2100359.	2.1	9
654	Fluorescence Molecular Targeting of Colon Cancer to Visualize the Invisible. Cells, 2022, 11, 249.	1.8	14

#	ARTICLE	IF	CITATIONS
655	Histopathological role of vitamin D deficiency in recurrent/chronic tonsillitis pathogenesis: Vascular epithelial growth factor-mediated angiogenesis in tonsil. <i>Clinical and Experimental Dental Research</i> , 2022, 8, 699-706.	0.8	6
656	Cotransplant With Pancreatic Islet Homogenate Improved Survival and Long-Term Efficacy of Islet Transplant in Streptozotocin-Diabetic Rats. <i>Experimental and Clinical Transplantation</i> , 2022, 20, 164-172.	0.2	1
657	Multiple LEDT wavelengths modulate the Akt signaling pathways and attenuate pathological events in mdx dystrophic muscle cells. <i>Photochemical and Photobiological Sciences</i> , 2022, 21, 1257-1272.	1.6	5
664	Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
665	Differentiation and Definition of Vascular-Targeted Therapies. <i>Clinical Cancer Research</i> , 2005, 11, 416-420.	3.2	230
666	Tetrahydrocurcumin-Related Vascular Protection: An Overview of the Findings from Animal Disease Models. <i>Molecules</i> , 2022, 27, 5100.	1.7	8
667	Differential dependency of human glioblastoma cells on vascular endothelial growth factor signaling via neuropilin-1. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	3
668	Immunosuppressive effects of vascular endothelial growth factor (Review). <i>Oncology Letters</i> , 2022, 24, .	0.8	11
669	Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial. <i>Eye and Vision (London, England)</i> , 2022, 9, .	1.4	3
670	Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review). <i>International Journal of Oncology</i> , 2023, 62, .	1.4	8
671	Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1536-1567.	1.0	3